Prodromal Markers in Recurrent Dream Enactment Behaviors Without REM Sleep Without Atonia
Launched by CHINESE UNIVERSITY OF HONG KONG · Apr 25, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a condition called REM Sleep Behavior Disorder (RBD), which involves unusual behaviors during dreaming, like acting out dreams while sleeping. The researchers are particularly interested in understanding a new idea called "prodromal RBD," where people show signs of RBD but do not fully meet the criteria for the disorder. This trial aims to investigate if certain behaviors, like acting out dreams without the usual sleep patterns, are linked to early signs of neurodegenerative diseases, such as Parkinson's disease.
To participate in this study, people need to be between 45 and 65 years old and have had repeated dream enactment behaviors. They will also need to have a specific score from a sleep behavior questionnaire indicating their symptoms. Participants will be interviewed and may have their sleep recorded to observe these behaviors. This trial is currently recruiting, and everyone is welcome to apply, regardless of gender. It's an important step in understanding sleep disorders and their potential links to other health issues.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age between 45 and 65 years old
- • RBDQ-HK behavior factor greater \> 8
- • Recurrent DEBs by interview and/or video analysis
- • Absence of sufficient RSWA
- Exclusion Criteria:
- • Age- and sex- matched with cases
- • RBDQ-HK behavior factor \< 8
- • No DEBs by either interview or video analysis
- • Absence of sufficient RSWA
About Chinese University Of Hong Kong
The Chinese University of Hong Kong (CUHK) is a prestigious research institution renowned for its commitment to advancing medical science and improving healthcare outcomes. As a clinical trial sponsor, CUHK leverages its extensive academic resources and interdisciplinary expertise to conduct innovative research that addresses critical health challenges. The university fosters collaboration among leading researchers, healthcare professionals, and industry partners, ensuring rigorous study design and implementation. CUHK is dedicated to upholding the highest ethical standards in clinical research, with a focus on translating findings into tangible benefits for patients and the broader community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shatin, , Hong Kong
Patients applied
Trial Officials
Yun Kwok Wing, Professor
Principal Investigator
Chinese University of Hong Kong
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials